EMILIA DISANTO ●NEW— Deputy Inspector General, US Department of State; Chief of Staff, Federal Housing Finance Agency Office of Inspector General; Chief Investigative Counsel & Special Counsel, US Senate Committee on FinanceJAKARA EASON ●NEW
IDs
Filing UUID:7b23c0d3-4dd2-46d2-90ea-1199bcadf0b3
Registrant ID:65191
Client ID:66611
2025-05-07
MR. DAN CRIPPEN
AMGEN
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
pharmacy pricing, R&D, chronic disease
Registered Lobbyists (1)
DAN CRIPPEN ●NEW
IDs
Filing UUID:fbebef47-d31b-407b-a9f4-02b0072afd1e
Registrant ID:401109565
Client ID:66449
2025-04-25
FIRST PRINCIPLES STRATEGIES, LLC
HORIZON GOVERNMENT AFFAIRS ON BEHALF OF U.S. PHARMACOPEIAL CONVENTION
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Nonprofit organization focused on building trust in the supply of safe, quality medicines.
Registered Lobbyists (1)
JOSEPH MURRAY ●NEW— Senator Ron Johnson, Rep. Mark Meadows, and Republican Study Committee
IDs
Filing UUID:082627ff-8336-4c11-be29-07f043500ff9
Registrant ID:401104348
Client ID:66291
2025-04-25
OLD NORTH STRATEGIES, LLC
HORIZON GOVERNMENT AFFAIRS ON BEHALF OF U.S. PHARMACOPEIAL CONVENTION
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Nonprofit organization focused on building trust in the supply of safe, quality medicines
Registered Lobbyists (1)
JOSEPH KING ●NEW— former Deputy Chief of Staff Congressman Mark Meadows & former Sr. Advisor Congressman Greg Murphy, MD
IDs
Filing UUID:c99c6370-eac0-42c0-a60c-b8344d51c409
Registrant ID:401106174
Client ID:66304
2025-04-24
REVVITY, INC.
REVVITY, INC.
$0
$30,000
Filing Details
Type: ld2 • Year: 2025 Q2
Specific Issues
Diagnostic test reimbursement and policies Genomic sequencing T-Cell Immune Response Testing Proposals related to newborn screening Proposals related to pandemic preparedness FDA Medical Device Product policies H.R. 2810, Family Cord Blood Banking Act; Medical Device & Pharmaceutical Adjacent Tariff
Government Entities
Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE, Bureau of Industry and Security (BIS)
Registered Lobbyists (1)
LUIS TOVAR ●NEW
IDs
Filing UUID:33bca1b0-cbdd-4445-b089-32fef0fc71e0
Registrant ID:401105953
Client ID:208897
2025-04-23
HORIZON GOVERNMENT AFFAIRS
THE UNITED STATES PHARMACOPEIAL CONVENTION
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Prescription drug issues and prescription drug supply chain
Registered Lobbyists (4)
COLTON HENNING ●NEWJOE MURRAY ●NEWJOEL WHITE ●NEW— Former Staff Director, Ways & Means Health Subcommittee; L.A. for Rep. Jim Greenwood; L.A. for Rep. Chris ShaysWAYNE KING ●NEW
IDs
Filing UUID:1b574bc8-51d9-43b4-958c-46569fa1f29e
Registrant ID:315592
Client ID:66248
2025-04-22
NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC
MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMER
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484; Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484; Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484; Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484; Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484
Registered Lobbyists (1)
ERIC SILVA ●NEW— Legislative Staff, Senate Environment and Public Works Committee and Senator James Jeffords
IDs
Filing UUID:675f6655-af62-4db2-8085-084482e2cdd8
Registrant ID:400689052
Client ID:66228
2025-04-17
FRONTLINE GOVERNMENT RELATIONS
EMPOWER PHARMACY
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Engage with federal agencies, members of Congress and congressional committees impacting pharmaceutical compounding and patient health issues.; Engage with federal agencies, members of Congress and congressional committees impacting pharmaceutical compounding and patient health issues.; Engage with federal agencies, members of Congress and congressional committees impacting pharmaceutical compounding and patient health issues.
Registered Lobbyists (1)
JOHN PENCE ●NEW
IDs
Filing UUID:c5b7ba88-51dc-4c09-8945-2ed30346733e
Registrant ID:401109481
Client ID:65940
2025-04-11
CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS
ORCHARD THERAPEUTICS NORTH AMERICA
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Issues around health and pharmaceuticals.; Issues around health and pharmaceuticals.; Issues around health and pharmaceuticals.
Registered Lobbyists (2)
MICHAEL CORCORAN ●NEWROBERT BLAIR ●NEW
IDs
Filing UUID:239c47b0-da68-471c-80a9-fbc05b0cccad
Registrant ID:401109009
Client ID:65681
2025-04-07
THE VOGEL GROUP
NEPHRON PHARMACEUTICALS CORPORATION
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q2
Specific Issues
Issues relating to facility operations
Registered Lobbyists (2)
ADRIAN JEWETT ●NEWALEXANDER VOGEL ●NEW— Former Chief Counsel, Senate Majority Leader Bill Frist
IDs
Filing UUID:4fc2578c-1b33-4c53-ba8d-cd8c081af99a
Registrant ID:401104734
Client ID:202541
2025-03-31
LANTHEUS HOLDINGS, INC.
LANTHEUS HOLDINGS, INC.
$0
$420,000
Filing Details
Type: ld2 • Year: 2025 Q1
Specific Issues
HOPPS separate payment for diagnostic radiopharmaceuticals
Government Entities
Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Registered Lobbyists (1)
IRA GOLDMAN
IDs
Filing UUID:9f9143c2-a026-4544-937d-c9ed0ad7eacf
Registrant ID:401105198
Client ID:203388
2025-03-28
PARATEK PHARMACEUTICALS
PARATEK PHARMACEUTICALS
$0
$10,000
Filing Details
Type: ld2 • Year: 2025 Q1
Specific Issues
FY 26 DOD Appropriations FY 26 HHS Appropriations Biodefense Funding
Government Entities
Defense, Dept of (DOD), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
Registered Lobbyists (1)
BENJAMIN NOVAK
IDs
Filing UUID:0571fd7a-b582-4359-baa7-bd2e29d76dc4
Registrant ID:401109327
Client ID:64825
2025-03-27
MILLS BLACK LLP
POPULUS MEDIA, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Respond to Senate inquiry re pharmaceutical marketing; Respond to Senate inquiry re pharmaceutical marketing
Registered Lobbyists (1)
THOMAS MILLS ●NEW
IDs
Filing UUID:86465423-5d5e-4c0c-b358-38852bbe0856
Registrant ID:401106427
Client ID:65261
2025-03-27
CHECKMATE GOVERNMENT RELATIONS
REGENERON PHARMACEUTICALS INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues related to healthcare.
Registered Lobbyists (2)
CHARLES MCDOWELL ●NEWFREDERICK VAUGHAN ●NEW— Principal Deputy Asst. Secretary, Treasury Dept.; Deputy Asst. Secretary, Treasury Dept.; Senior Counsel, House Financial Services Cmte.; Associate Director, The White House; Confidential Asst., Office of Management & Budget; Writer, The White House
Issues related to pain management.; Issues related to pain management.; Issues related to pain management.; Issues related to pain management.
Registered Lobbyists (2)
HAZEN MARSHALL ●NEW— Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don NicklesMONICA POPP ●NEW— Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint
IDs
Filing UUID:ae6090a1-0bc2-4ba7-acbc-72f04dc0a493
Registrant ID:401105121
Client ID:65129
2025-03-24
BECKER & POLIAKOFF, P.A.
JOHNSON & JOHNSON SERVICES, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
pharmaceutical, biotechnology, and medical technologies issues
Registered Lobbyists (2)
NERI MARTINEZ ●NEW— Staff Director, Senate Special Committee on Aging Committee; Chief of Staff, Sen. Tim Scott; Chief of Staff, Dept. of Energy Office of Economic ImpactOMAR FRANCO ●NEW— Chief of Staff, Rep. Mario Diaz-Balart
IDs
Filing UUID:e6e392ff-e18c-466c-a170-c4be6351a227
Registrant ID:283696
Client ID:65151
2025-03-20
BGR GOVERNMENT AFFAIRS
DIGNITY AND WELLNESS PATIENT SOLUTIONS, LLC
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Provide strategic counsel and advocate on issues related to providing LTC pharmacy services
Registered Lobbyists (3)
CHRIS KELLY ●NEW— Health Policy Dir., Leg. Asst., Leg. Corr., Front Office Coordinator, Staff Asst. Sen. BlackburnJOEL BAILEY ●NEW— COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA, Sr. LA Rep. Baron Hill; Intern Rep. RahallRAGHAV AGGARWAL ●NEW— Health Insurance Specialist, CMS; Senior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden; Social Science Research Analyst, CMS; Intern, Sen. Feinstein; Secretarys Fellow, US Dept. of Interior
IDs
Filing UUID:32b6f3a6-3691-4420-a557-efcc94e5d3a9
Registrant ID:5357
Client ID:65060
2025-03-18
FOLEY & LARDNER LLP
ASSOCIATION FOR ACCESSIBLE MEDICINES
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues related to generic and biosimilar manufacturing and pharmaceutical trade.; Issues related to generic and biosimilar manufacturing and pharmaceutical trade.; Issues related to generic and biosimilar manufacturing and pharmaceutical trade.
Registered Lobbyists (1)
JOHN STROM ●NEW— Senior Counsel - U.S. House Cmte on Energy & Commerce; Counsel - U.S. Senate Cmte on Health, Education, Labor, and Pensions; Associate General Counsel - U.S. Dept of Health and Human Services; Senior Counsel - U.S. House Cmte on Natural Resources
IDs
Filing UUID:06ab37ab-2a40-472a-a6bf-37b492e6c285
Registrant ID:15042
Client ID:64990
2025-03-17
DLA PIPER LLP (US)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.; Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.; Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.; Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.; Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.; Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Registered Lobbyists (4)
KARINA LYNCH ●NEWMARGARET MARTIN ●NEW— Senior FDA Policy Advisor, Senate Health, Education, Labor and Pensions Committee; Health Policy Assistant, Sen. Richard BurrRACHEL PORTMAN ●NEW— Deputy Health Policy Director, Committee on Senate Health, Education, Labor and Pensions; Health Policy Assistant, Sen. Richard Burr; Intern, Rep. Robert PortmanRICHARD BURR ●NEW— U.S. Senator
Various issues facing the healthcare industry, including drug development regulation, health insurance regulation, and pharmaceutical industry regulation.; Various issues facing the healthcare industry, including drug development regulation, health insurance regulation, and pharmaceutical industry regulation.; Various issues facing the healthcare industry, including drug development regulation, health insurance regulation, and pharmaceutical industry regulation.
Registered Lobbyists (1)
TUCKER BROWN ●NEW
IDs
Filing UUID:84dfd032-4f0b-428d-80d5-a036d0d22800
Registrant ID:401109366
Client ID:64922
2025-03-14
CHECKMATE GOVERNMENT RELATIONS
GSK
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Focused engagement with HHS regarding pharmaceutical technology.; Focused engagement with HHS regarding pharmaceutical technology.
Registered Lobbyists (2)
CHARLES MCDOWELL ●NEWFREDERICK VAUGHAN ●NEW— Principal Deputy Asst. Secretary, Treasury Dept.; Deputy Asst. Secretary, Treasury Dept.; Senior Counsel, House Financial Services Cmte.; Associate Director, The White House; Confidential Asst., Office of Management & Budget; Writer, The White House
IDs
Filing UUID:551cb098-e8b9-4e86-bc01-020c8be98fc8
Registrant ID:401109039
Client ID:64838
2025-03-13
TAUZIN STRATEGIC NETWORKS
RAZORMETRICS
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Coordination with Medicaid to reduce pharmacy expenses and help improve patient outcomes
Registered Lobbyists (1)
W.J. TAUZIN ●NEW
IDs
Filing UUID:56e32462-e710-471e-80db-a25d2e4b1871
Registrant ID:400786367
Client ID:64818
2025-03-13
THORN RUN PARTNERS
BRIDGEBIO PHARMA, INC.
$30,000
$0
Filing Details
Type: ld2 • Year: 2025 Q1
Specific Issues
Issues related to the treatment of rare diseases.; Issues related to the treatment of rare diseases.